WALTHAM,
Mass., Sept. 10, 2024 /PRNewswire/ -- Spyre
Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology
company utilizing best-in-class antibody engineering, rational
therapeutic combinations, and precision medicine approaches to
target improved efficacy and convenience in the treatment of
Inflammatory Bowel Disease ("IBD"), today announced that management
will participate in a fireside chat and investor meetings at the
Stifel 2024 Virtual Immunology and Inflammation Summit. Details of
the fireside are as follows:
- Wednesday, September 18, 2024, at
12:00 p.m. Eastern time
A webcast replay will be available on the Spyre investor events
website for 90 days following the event.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company
that aims to create next-generation inflammatory bowel disease
(IBD) products by combining best-in-class antibody engineering,
rational therapeutic combinations, and precision medicine
approaches. Spyre's pipeline includes extended half-life antibodies
targeting α4β7, TL1A, and IL-23. For more information, visit
Spyre's website at www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and
LinkedIn
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-upcoming-investor-conference-302244312.html
SOURCE Spyre Therapeutics, Inc.